deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 3-arm NCT02812706

Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients (Islands)

A Phase I/II Study of Isatuximab (Anti-CD38 mAb) Administered as a Single Agent in Japanese Patients With Relapsed and Refractory Multiple Myeloma

Sponsor: Sanofi

Conditions Multiple Myeloma
Interventions Isatuximab SAR650984
Updated 25 times since 2017 Last updated: Sep 26, 2023 Started: Sep 5, 2016 Primary completion: Jul 31, 2018 Completion: Sep 28, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02812706, this PHASE1/PHASE2 trial focuses on Multiple Myeloma and remains completed. Sponsored by Sanofi, it has been updated 25 times since 2016, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Jun 2017 · 5 months · monthly snapshot~Jun 2017 – ~Jul 2017 · 30 days · monthly snapshot~Jul 2017 – ~Aug 2017 · 31 days · monthly snapshot~Aug 2017 – ~Sep 2017 · 31 days · monthly snapshot~Sep 2017 – ~Oct 2017 · 30 days · monthly snapshot~Oct 2017 – ~Feb 2018 · 4 months · monthly snapshot~Feb 2018 – ~Mar 2018 · 28 days · monthly snapshot~Mar 2018 – ~May 2018 · 2 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Feb 2019 · 5 months · monthly snapshot~Feb 2019 – ~Nov 2019 · 9 months · monthly snapshot~Nov 2019 – ~Jul 2020 · 8 months · monthly snapshot~Jul 2020 – ~Oct 2020 · 3 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Nov 2021 · 10 months · monthly snapshot~Nov 2021 – ~Jun 2022 · 7 months · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Dec 2022 · 3 months · monthly snapshot~Dec 2022 – ~May 2024 · 17 months · monthly snapshot~May 2024 – ~Jul 2024 · 2 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

25 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. May 2024 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  5. Dec 2022 — May 2024 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not Recruiting → Completed

▶ Show 20 earlier versions

  1. Sep 2022 — Dec 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  2. Jul 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  3. Jun 2022 — Jul 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  4. Nov 2021 — Jun 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. Jan 2021 — Nov 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  6. Oct 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  7. Jul 2020 — Oct 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  8. Nov 2019 — Jul 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  9. Feb 2019 — Nov 2019 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  10. Sep 2018 — Feb 2019 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  11. Jun 2018 — Sep 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  12. May 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  13. Mar 2018 — May 2018 [monthly]

    Recruiting PHASE1_PHASE2

  14. Feb 2018 — Mar 2018 [monthly]

    Recruiting PHASE1_PHASE2

  15. Oct 2017 — Feb 2018 [monthly]

    Recruiting PHASE1_PHASE2

  16. Sep 2017 — Oct 2017 [monthly]

    Recruiting PHASE1_PHASE2

  17. Aug 2017 — Sep 2017 [monthly]

    Recruiting PHASE1_PHASE2

  18. Jul 2017 — Aug 2017 [monthly]

    Recruiting PHASE1_PHASE2

  19. Jun 2017 — Jul 2017 [monthly]

    Recruiting PHASE1_PHASE2

  20. Jan 2017 — Jun 2017 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Sep 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Sanofi
Data source: Sanofi

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Chuo-ku, Japan , Hiroshima, Japan , Kanazawa, Japan , Kyoto, Japan , Nagoya, Japan , Okayama, Japan , Osaka, Japan , Shibukawa-shi, Japan , Shibuya-ku, Japan , Suita-shi, Japan and 3 more locations